{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:21:22Z","timestamp":1790230882499,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,6,5]],"date-time":"2011-06-05T00:00:00Z","timestamp":1307232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00280-011-1684-y","type":"journal-article","created":{"date-parts":[[2011,6,4]],"date-time":"2011-06-04T10:45:35Z","timestamp":1307184335000},"page":"185-194","source":"Crossref","is-referenced-by-count":17,"title":["Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy"],"prefix":"10.1007","volume":"69","author":[{"given":"William S.","family":"Holland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford G.","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose E.","family":"Pietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle C.","family":"Chinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,5]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O\u2019Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271\u20132281","journal-title":"N Engl J Med"},{"key":"1684_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449\u2013456","journal-title":"Lancet"},{"key":"1684_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","volume":"7","author":"PH Patel","year":"2009","unstructured":"Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7:24\u201327","journal-title":"Clin Genitourin Cancer"},{"key":"1684_CR4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","volume":"28","author":"JD Hainsworth","year":"3rd","unstructured":"Hainsworth JD, Spigel DR, Burris HA, 3rd, Waterhouse D, Clark BL, Whorf R (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28:2131\u20132136","journal-title":"J Clin Oncol"},{"key":"1684_CR5","first-page":"15s","volume":"28","author":"BJ Escudier","year":"2010","unstructured":"Escudier BJ, Negrier S, G. Gravis, C. Chevreau, R. Delva, J. Bay, L. Geoffrois, E. Legouffe, E. Blanc, C. Ferlay (2010) Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 28:15s (suppl; abstr 4516)","journal-title":"J Clin Oncol"},{"key":"1684_CR6","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26:1932\u20131940","journal-title":"Oncogene"},{"key":"1684_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3816\/CGC.2007.n.031","volume":"5","author":"KG Chee","year":"2007","unstructured":"Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN Jr (2007) The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California\/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 5:433\u2013437","journal-title":"Clin Genitourin Cancer"},{"key":"1684_CR8","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/1078-0432.CCR-03-0406","volume":"10","author":"L Ummersen Van","year":"2004","unstructured":"Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G (2004) A phase I trial of perifosine (NSC 639966) on a loading dose\/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10:7450\u20137456","journal-title":"Clin Cancer Res"},{"key":"1684_CR9","first-page":"1093","volume":"2","author":"SB Kondapaka","year":"2003","unstructured":"Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2:1093\u20131103","journal-title":"Mol Cancer Ther"},{"key":"1684_CR10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00404-010-1457-6","volume":"283","author":"JB Engel","year":"2011","unstructured":"Engel JB, Schonhals T, Hausler S, Krockenberger M, Schmidt M, Horn E, Koster F, Dietl J, Wischhusen J, Honig A (2011) Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch Gynecol Obstet 283:603\u2013610","journal-title":"Arch Gynecol Obstet"},{"key":"1684_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/JTO.0b013e31819c78fb","volume":"4","author":"PR Purnell","year":"2009","unstructured":"Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O (2009) The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol 4:448\u2013454","journal-title":"J Thorac Oncol"},{"key":"1684_CR12","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315\u20132319","journal-title":"Nat Protoc"},{"key":"1684_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/pros.20548","volume":"67","author":"CG Tepper","year":"2007","unstructured":"Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW (2007) GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate 67:521\u2013535","journal-title":"Prostate"},{"key":"1684_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/pros.20308","volume":"65","author":"CG Tepper","year":"2005","unstructured":"Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW (2005) Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 65:375\u2013389","journal-title":"Prostate"},{"key":"1684_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/biostatistics\/4.2.249","volume":"4","author":"RA Irizarry","year":"2003","unstructured":"Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249\u2013264","journal-title":"Biostatistics"},{"key":"1684_CR16","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"key":"1684_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.lungcan.2005.07.002","volume":"50","author":"L Boldrini","year":"2005","unstructured":"Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Basolo F, Pingitore R, Fontanini G (2005) Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Lung Cancer 50:309\u2013317","journal-title":"Lung Cancer"},{"key":"1684_CR18","doi-asserted-by":"publisher","first-page":"20522","DOI":"10.1074\/jbc.M109.025346","volume":"284","author":"D Kawanami","year":"2009","unstructured":"Kawanami D, Mahabeleshwar GH, Lin Z, Atkins GB, Hamik A, Haldar SM, Maemura K, Lamanna JC, Jain MK (2009) Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium. J Biol Chem 284:20522\u201320530","journal-title":"J Biol Chem"},{"key":"1684_CR19","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-05-2519","volume":"66","author":"VA Carroll","year":"2006","unstructured":"Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66:6264\u20136270","journal-title":"Cancer Res"},{"issue":"1376","key":"1684_CR20","first-page":"1372","volume":"32","author":"PY Muller","year":"2002","unstructured":"Muller PY, Janovjak H, Miserez AR, Dobbie Z (2002) Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372\u20131374(1376), 1378\u20131379","journal-title":"Biotechniques"},{"key":"1684_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/bioinformatics\/btg157","volume":"19","author":"P Simon","year":"2003","unstructured":"Simon P (2003) Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics 19:1439\u20131440","journal-title":"Bioinformatics"},{"key":"1684_CR22","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","volume":"5","author":"E Buck","year":"2006","unstructured":"Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5:2676\u20132684","journal-title":"Mol Cancer Ther"},{"key":"1684_CR23","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","volume":"38","author":"M Crul","year":"2002","unstructured":"Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38:1615\u20131621","journal-title":"Eur J Cancer"},{"key":"1684_CR24","doi-asserted-by":"publisher","first-page":"8967","DOI":"10.1158\/0008-5472.CAN-09-2190","volume":"69","author":"L Fu","year":"2009","unstructured":"Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, Sun SY (2009) Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69:8967\u20138976","journal-title":"Cancer Res"},{"key":"1684_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"1684_CR26","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1074\/jbc.M707882200","volume":"283","author":"J Wu","year":"2008","unstructured":"Wu J, Bohanan CS, Neumann JC, Lingrel JB (2008) KLF2 transcription factor modulates blood vessel maturation through smooth muscle cell migration. J Biol Chem 283:3942\u20133950","journal-title":"J Biol Chem"},{"key":"1684_CR27","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1074\/jbc.M806928200","volume":"284","author":"K Sako","year":"2009","unstructured":"Sako K, Fukuhara S, Minami T, Hamakubo T, Song H, Kodama T, Fukamizu A, Gutkind JS, Koh GY, Mochizuki N (2009) Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase\/AKT-dependent activation of myocyte enhancer factor 2. J Biol Chem 284:5592\u20135601","journal-title":"J Biol Chem"},{"key":"1684_CR28","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/01.RES.0000159707.05637.a1","volume":"96","author":"Z Lin","year":"2005","unstructured":"Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan DE, Gimbrone MA Jr, Balasubramanian V, Garcia-Cardena G, Jain MK (2005) Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 96:e48\u2013e57","journal-title":"Circ Res"},{"key":"1684_CR29","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/cncr.20887","volume":"103","author":"S Fukata","year":"2005","unstructured":"Fukata S, Inoue K, Kamada M, Kawada C, Furihata M, Ohtsuki Y, Shuin T (2005) Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 103:931\u2013942","journal-title":"Cancer"},{"key":"1684_CR30","first-page":"1519","volume":"19","author":"B Konig","year":"1999","unstructured":"Konig B, Steinbach F, Janocha B, Drynda A, Stumm M, Philipp C, Allhoff EP, Konig W (1999) The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma. Anticancer Res 19:1519\u20131524","journal-title":"Anticancer Res"},{"key":"1684_CR31","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-09-3965","volume":"70","author":"D Huang","year":"2010","unstructured":"Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063\u20131071","journal-title":"Cancer Res"},{"key":"1684_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1476-511X-9-33","volume":"9","author":"JM Jimenez-Lopez","year":"2010","unstructured":"Jimenez-Lopez JM, Rios-Marco P, Marco C, Segovia JL, Carrasco MP (2010) Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis 9:33","journal-title":"Lipids Health Dis"},{"key":"1684_CR33","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1158\/1535-7163.MCT-07-0202","volume":"6","author":"AH Luit van der","year":"2007","unstructured":"van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, van Blitterswijk WJ (2007) A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther 6:2337\u20132345","journal-title":"Mol Cancer Ther"},{"key":"1684_CR34","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/nature06613","volume":"451","author":"Z Arany","year":"2008","unstructured":"Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM (2008) HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451:1008\u20131012","journal-title":"Nature"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1684-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1684-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1684-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1684-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:30:55Z","timestamp":1581960655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1684-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1684-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,5]]}}}